Table 1 General characteristics of the overall population with ventilator acquired pneumonia
Study group | ||||
|---|---|---|---|---|
Characteristic | Overall, N = 2031 | NON-COVID-19, N = 781 | COVID-19, N = 1251 | p-value2 |
Sex, male | 149 (73%) | 55 (71%) | 94 (75%) | 0.5 |
Age, years | 64 (55, 73) | 69 (56, 77) | 63 (54, 71) | 0.013 |
BMI, kg/m2 | 27 (24, 31) | 25 (23, 29) | 29 (26, 31) | 0.003 |
Solid organ transplant | 25 (12%) | 19 (24%) | - | |
Cardiovascular comorbidities | 50 (25%) | 29 (37%) | 21 (17%) | 0.001 |
Diabetes type II | 36 (18%) | 10 (13%) | 26 (21%) | 0.15 |
CKD | 27 (13%) | 21 (27%) | 6 (4.8%) | < 0.001 |
Respiratory comorbidities | 27 (13%) | 13 (17%) | 14 (11%) | 0.3 |
Alcohol or drug abusers | 7 (3.5%) | 2 (2.6%) | 5 (4.0%) | 0.7 |
Cirrhosis | 3 (1.5%) | 3 (3.8%) | 0 (0%) | 0.055 |
Immunodepression | 16 (7.9%) | 10 (13%) | 6 (4.8%) | 0.039 |
Immunosuppressive therapy | 25 (12%) | 19 (24%) | 6 (4.8%) | < 0.001 |
Cyclosporin | 8 (3.9%) | 8 (10%) | 0 (0%) | < 0.001 |
Tacrolimus/Everolimus | 3 (1.5%) | 3 (3.8%) | 0 (0%) | 0.055 |
Azathioprine | 3 (1.5%) | 3 (3.8%) | 0 (0%) | 0.055 |
Mofetyl Mycophenolate | 9 (4.4%) | 9 (12%) | 0 (0%) | < 0.001 |
Metothrexate | 1 (0.5%) | 0 (0%) | 1 (0.8%) | > 0.9 |
Steroids | 19 (9.4%) | 18 (23%) | 1 (0.8%) | < 0.001 |
ECMO support | 56 (28%) | 17 (22%) | 39 (31%) | 0.14 |
RRT | 48 (24%) | 32 (41%) | 16 (13%) | < 0.001 |
SAPS II score | 52 (42, 58) | 54 (43, 62) | 51 (41, 57) | 0.2 |
SOFA score | 10 (8, 12) | 10 (8, 13) | 9 (7, 11) | < 0.001 |